ADMS Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The Company is developing its wholly-owned product candidate, ADS-5102.

As of 09/16/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  04/10/2014
Outstanding shares:  45,595,824
Average volume:  160,921
Market cap:   $212,020,582
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    00548A106
ISIN:        US00548A1060
Sedol:      BL25XY4
Valuation   (See tab for details)
PE ratio:   -3.93
PB ratio:   36.26
PS ratio:   2.57
Return on equity:   1,366.38%
Net income %:   -66.82%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy